Back to Academy

Medical Device Post-Market Surveillance: The Complete Guide

Under the EU Medical Device Regulation (MDR) and the UK Medical Devices Regulations 2002 (UK MDR), post-market oversight is split between two complementary mechanisms: post-market surveillance (PMS) and post-market clinical follow-up (PMCF).

PMS is the overarching system for collecting all quality, performance and safety data. PMCF is the proactive clinical arm of PMS, focused on clinical safety and risks. In pharmaceutical terms, PMCF is the closest equivalent to Phase IV post-marketing studies, while PMS covers the wider regulatory system around it.

PMS is an end-to-end regulatory requirement across the EU and the UK. This guide explains why post-market surveillance matters and gives a clear overview of the UK, EU and US requirements.

In short

  • Definition: Medical device post-market surveillance (PMS) is a continuous, systematic process through which manufacturers collect, analyse and act on real-world safety, performance and clinical data from devices in clinical use.
  • Primary objective: To proactively identify emerging risks, prevent serious incidents, confirm the ongoing benefit-risk ratio, and inform product improvements and regulatory updates (PMSR/PSUR).
  • Regulatory mandate: Required in Great Britain under Part 4A of the UK Medical Devices Regulations 2002 (SI 2024 No. 1368) and in the EU under Regulation (EU) 2017/745 (MDR) Chapter VII.
  • Who is Ledidi? Ledidi is a Norwegian software company founded by academic surgeons and software engineers. We provide a unified, secure cloud platform, comprising Ledidi Core, Ledidi Trials and Ledidi Registries, that combines data capture, real-time analytics and global collaboration.

What is post-market surveillance (PMS) for medical devices?

Post-market surveillance (PMS) is the structured process of monitoring the safety and performance of a medical device once it is made available on the market. Safety and performance are tracked in a PMS system, which draws on post-market clinical follow-up data to keep the clinical evaluation up to date. PMS is an essential part of ensuring high-quality medical devices through the entire lifecycle, and it is closely linked to the broader framework of vigilance and market oversight.

Definition by the European Medical Device Regulation (MDR)

"'Post-market surveillance' means all activities carried out by manufacturers in cooperation with other economic operators to institute and keep up to date a systematic procedure to proactively collect and review experience gained from devices they place on the market, make available on the market or put into service for the purpose of identifying any need to immediately apply any necessary corrective or preventive actions."
EU Medical Device Regulation (MDR), Article 2(60)

Post-market surveillance is part of the larger quality management system

Medical device manufacturers rely on a quality management system (QMS) to ensure the safe and appropriate use of their products. The QMS includes a PMS system, which in turn consists of a post-market surveillance plan (PMS plan), a post-market surveillance report (PMSR) and a periodic safety update report (PSUR). Together, these ensure systematic, active data collection in line with regulatory requirements.

What really happens during post-market surveillance?

During PMS, manufacturers generate, collect and analyse real-world data on the device and its use. Once they have processed that data, they can use the insights to:

  • Discover safety issues with the design or use of the device.
  • Understand how the device is used once it is deployed in real-world settings.
  • Gather clinical evidence on how the device performs, which also supports its commercial use cases.
  • Collect data that drives improvements and informs the next iteration of the device.
  • Comply with global regulatory requirements.

A post-market surveillance plan: clinical evaluation in practice

According to EU MDR Article 84 and Part 4A of the UK MDR, post-market surveillance activities cannot be carried out ad hoc. They must be structured within a formal post-market surveillance plan.

The PMS plan forms an integral part of the device's technical documentation. It must show that the manufacturer has established a proactive, systematic process that is proportionate to the risk class and intended purpose of the device.

Template structure for a PMS plan

To satisfy notified bodies and the MHRA, manufacturers should structure their PMS plan around the following sections:

SectionContentObjective
Scope and classification of the deviceDevice description, trade name, risk class (Class I, IIa, IIb, III or IVD), UDI and expected product lifetime.Establishes the regulatory baseline and reporting proportionality.
Roles and responsibilitiesDesignation of the Person Responsible for Regulatory Compliance (PRRC), vigilance managers and clinical evaluators.Establishes clear governance and operational accountability.
Proactive strategyDefined protocols for post-market clinical follow-up (PMCF), clinical registry data collection, user surveys and systematic literature screening.Uncovers unknown residual risks and verifies state-of-the-art performance.
Reactive strategyWorkflows for capturing customer complaints, servicing records, adverse incident notifications and recalls of competitor devices.Identifies acute technical failures and usability issues.
Data analysis and reporting thresholdsPredefined statistical methods, unacceptable incident frequency rates and signal detection criteria.Triggers mandatory corrective and preventive actions (CAPA) or safety notices.
CAPA and field safety workflowsDefined escalation paths for Field Safety Notices (FSN) and Field Safety Corrective Actions (FSCA).Puts rapid risk mitigation into practice to protect public health.
Reporting and documentationSchedules and responsibilities for drafting the post-market surveillance report (PMSR) or periodic safety update report (PSUR).Ensures timely statutory submissions to the MHRA and notified bodies.

Get a full overview of the contents of a PMS plan in this guidance from the Medical Device Coordination Group (MDCG) (PDF).

An essential component of the PMS plan for CE-marked and UKCA devices is the PMCF plan, or a documented justification for why PMCF is not applicable. While the PMS plan monitors overall quality and technical performance, the PMCF plan focuses strictly on clinical safety, residual risks and real-world outcomes.

Get an overview of the contents of a PMCF plan in our guide to PMCF activities.

Why manufacturers must consider the entire medical device lifecycle

Medical devices are approved on the basis of clinical investigations in a relatively small group of people, selected against certain criteria (for example, no underlying medical conditions). Once the device is on the market, it is exposed to a much larger population with a wide variety of medical conditions. PMS gives manufacturers insight into the safety of the device when it is used by the general public, and that insight can be used to refine, confirm or challenge its properties.

Why post-market surveillance is crucial

Apart from being a requirement of regulators worldwide, a lifecycle perspective offers crucial insight into patient safety. If PMS is not prioritised, you will not only be non-compliant but may also miss signs of safety issues with your device. In the worst case, this can lead to a patient's death. Lower-risk scenarios can still damage your reputation, for example if a product does not function properly.

Staying proactive throughout the lifecycle

Do not make post-market surveillance an afterthought. Staying proactive gives you insight into key device properties such as production difficulty, materials, supplier communication or marketing efforts. With more information on how the product performs, production teams can fix issues and reduce a problem before it really becomes a problem.

Post-market surveillance in Europe: MDR and MDCG

Before a medical device can be placed on the European market, it must comply with the requirements of the EU MDR. Defined in Chapter VII and Annex III, the EU MDR requires manufacturers to establish a comprehensive PMS system integrated into their QMS.

The PMS system must actively gather, record and analyse relevant data on the quality, performance and safety of a device throughout its lifecycle. This keeps the benefit-risk determination continuously positive and ensures the technical documentation is updated with real-world evidence.

Reading best practices in MDCG guidance

Published by the Medical Device Coordination Group (MDCG), MDCG 2025-10 (December 2025), "Guidance on post-market surveillance of medical devices and in vitro diagnostic medical devices", offers comprehensive guidance on best practices for PMS under the MDR. Related MDCG guidance can be grouped as follows:

  • Safety and performance. MDCG 2022-21 clarifies the requirements for drafting, structuring and updating PSURs for moderate- and high-risk devices under MDR Article 86.
  • Compliance. MDCG 2021-25 outlines how PMS and vigilance obligations apply to pre-existing CE-marked devices transitioning to the MDR.
  • Lifecycle management. MDCG 2020-7 and MDCG 2020-8 provide standardised templates for the PMCF plan and the PMCF evaluation report.

These documents emphasise three operational pillars: proactive data generation, transparent reporting to notified bodies and authorities, and rapid implementation of Field Safety Corrective Actions (FSCA).

Post-market surveillance in the UK

In the United Kingdom, medical devices are regulated by the Medical Devices Regulations 2002 (UK MDR), which govern the sale, registration and safety of medical devices across Great Britain (England, Scotland and Wales). The post-market surveillance requirements in Part 4A of the UK MDR have applied since 16 June 2025. The Medicines and Healthcare products Regulatory Agency (MHRA) oversees medical device regulation in the UK.

The MHRA reporting system

For reporting during post-market surveillance, manufacturers use the MHRA's Manufacturer's On-line Reporting Environment (MORE) portal. It is used to register devices, including custom-made devices and systems, to log vigilance and incident reports, and to receive clinical study notifications.

Reporting is risk-proportional, with obligations that separate low-risk devices from moderate- and high-risk devices:

  • Post-market surveillance report (PMSR). Mandatory for low-risk devices (Class I). The PMSR summarises the results and conclusions of PMS data, along with any corrective actions taken. It must be updated when necessary and submitted to the MHRA on request.
  • Periodic safety update report (PSUR). Mandatory for moderate- and high-risk devices (Class IIa, Class IIb and Class III). The PSUR is a detailed, recurring document that outlines the continuous benefit-risk evaluation, findings from PMCF studies, sales volumes and population exposure estimates:
    • Class IIb and Class III devices: update the PSUR at least annually.
    • Class IIa devices: update the PSUR at least every two years.

Indefinite recognition of CE-marked devices (October 2026)

On 21 October 2026, the UK government confirmed that Great Britain will continue to accept CE-marked medical devices and IVDs indefinitely, following a public consultation that received more than 1,000 responses. More than 90% of medical devices registered in Great Britain carry a CE mark, and manufacturers will not need a separate UK approval for devices already approved for the EU market. UKCA marking remains the domestic route and is being modernised.

The decision does not reduce post-market obligations. According to the MHRA, the arrangements sit alongside the strengthened post-market surveillance and reporting requirements already in place, and the MHRA will continue to oversee every device on the UK market. CE-marked devices placed on the GB market must still meet the Part 4A PMS requirements that have applied since June 2025. Getting onto the market is becoming simpler while oversight after launch is getting closer, so a PMS system that produces evidence for both EU notified bodies and the MHRA is worth designing from the start.

Post-market surveillance in the US

In the United States, post-market surveillance is overseen by the Food and Drug Administration (FDA). The FDA's post-market requirements for devices sit in several parts of Title 21 of the Code of Federal Regulations (CFR):

  • Medical Device Reporting (21 CFR Part 803): manufacturers must report deaths and serious injuries that their device may have caused or contributed to, and malfunctions that would be likely to do so if they recurred. Reports are generally due within 30 calendar days, or within 5 working days where remedial action is needed to prevent an unreasonable risk of substantial harm.
  • Corrections and removals (21 CFR Part 806): field corrections and removals carried out to reduce a risk to health must be reported within 10 working days.
  • Section 522 postmarket surveillance (21 CFR Part 822): the FDA can order manufacturers of certain Class II and Class III devices to run post-market studies, for example where failure would have serious health consequences or the device is implanted for more than a year.
  • Post-approval studies: devices approved through the Premarket Approval (PMA) pathway often carry post-approval study conditions in their approval order (21 CFR 814.82).
  • Quality Management System Regulation (21 CFR Part 820): since 2 February 2026, the QMSR incorporates ISO 13485:2016 by reference, which brings US complaint handling and CAPA requirements closer to those in Europe.

Reports submitted under Part 803 are published in the FDA's MAUDE database. Unlike the EU MDR, US rules do not require a general PMS plan or periodic safety update reports for every device. However, the FDA increasingly accepts real-world evidence, including registry data, to support regulatory decisions.

Approaches to post-market surveillance

All data collected during PMS is reviewed to identify potential safety concerns. This involves signal detection and data mining across large datasets to find hidden patterns, correlations and anomalies. MedTech teams work with two broad kinds of data, reactive and proactive, which form the basis of their analysis.

Reactive data sources

Reactive methods gather vigilance and incident feedback. The most common sources are customer complaints, servicing or maintenance records and adverse incident vigilance reports.

Key spontaneous adverse incident databases include:

  • MHRA MORE portal in the UK
  • FDA MAUDE in the US
  • Eudamed vigilance module in the EU (not yet mandatory; until it is, serious incidents are reported to national competent authorities)

Proactive data sources

Proactive data collection means actively seeking out real-world clinical and operational performance data before adverse incidents occur. Key sources include:

  • Post-market clinical follow-up (PMCF) studies
  • Patient and clinical registries
  • User surveys
  • Literature reviews
  • State-of-the-art benchmarking

Enabling proactivity through smarter collaborative tools

MedTech manufacturers often struggle to collect structured, audit-ready data on a device once it is on the market. When they ask hospitals and clinics for follow-up data, they are often met with spreadsheets. That is not only an efficiency problem but a clear compliance risk.

At the same time, heavy clinical trial EDC systems are too rigid and costly for continuous PMS registries, which are essential for a realistic view of a device's use, benefits and potential pitfalls.

One answer is a unified cloud platform like Ledidi's. With Ledidi Registries and Ledidi Core, device manufacturers can collaborate with hospital registries and researchers in a compliant way.

Case in point: CMR Surgical's global real-world data registry

CMR Surgical built a prospective, international registry into the rollout of its Versius robotic surgical system from the first human case. Running on Ledidi, the registry captures patient characteristics, intra-operative outcomes and 30-day post-operative outcomes from participating hospitals worldwide. Data is entered as part of routine care, so the evidence base grows continuously instead of being reconstructed when a question arises.

The registry now produces peer-reviewed evidence on its own. A first analysis of 2,083 cases reported low intra- and post-operative complication rates across colorectal, general, gynaecological and urological surgery (Soumpasis et al., 2023). In 2026, surgeons at the Sindh Institute of Urology and Transplantation (SIUT) in Karachi, Pakistan, published the largest Versius series to date: 2,239 procedures performed by 20 surgeons between 2021 and 2025, analysed with the registry as the sole data source and with over 98% completeness for all but one variable (Rizvi et al., 2026).

CMR Surgical also used Ledidi's software for clinical trials and registries to validate data efficiently and safely across NHS hospitals. Mark Slack, Chief Medical Officer and Co-founder of CMR Surgical, has underlined the importance of data-driven clinical practice, which the Ledidi solution makes possible.

Read the full customer success story

What notified bodies and experts expect from PMS in 2026

At the MedTech Summit in Berlin in June 2026, notified bodies, regulators and manufacturers kept returning to one theme: the weight of clinical evidence for medical devices is moving from pre-market to post-market. These points from the sessions are useful for anyone planning or updating a PMS system.

  • "No complaints" is no longer evidence of safety. Under the old Medical Device Directive, an absence of complaints was often accepted as a sign that a device performed well. Under the MDR, notified bodies expect device-specific signals, predefined thresholds that trigger an update of the clinical evaluation report (CER), and several complementary data sources.
  • Risk management is becoming continuous. Manufacturers and notified bodies on a panel on balancing risk described a shift from static, predefined acceptance criteria to assessing each significant event against the risk file as it happens, rather than once a year. The European Commission's December 2025 proposal to revise the MDR (COM(2025) 1023) points the same way, although it is still a proposal and not yet law.
  • Clinical evaluation, risk management and PMS are one process. Gaps identified in the CER should map directly to PMCF activities, and PMS findings should feed back into both the CER and the risk file. Notified bodies treat a clinical evaluation plan that was visibly written after the report as a major non-conformity.
  • Expert panels are asking for more post-market data. A former notified body assessor presented an analysis of 18 published opinions from the EU expert panels: half required additional PMCF, including one for a device supported by a randomised controlled trial.
  • Registries are the accepted route for difficult cases. For orphan, breakthrough and high-risk devices, regulators increasingly accept less pre-market data in exchange for structured post-market follow-up, often through a registry. Speakers were equally clear that a registry is only as useful as the quality of the data entered into it.

In which phase is post-market surveillance done?

Clinical trial phases (I to IV) apply mostly to the study and approval of pharmaceutical products. Medical devices go through a comparable sequence under different names: Phases I and II are merged into one exploratory pilot phase, followed by a confirmatory pivotal phase (the counterpart of Phase III) and then the post-market phase.

PMS itself is not a trial phase. It is a regulatory obligation that runs for as long as a device is on the market. The clinical part of PMS, PMCF, takes place in the post-market phase and is the MedTech equivalent of Phase IV clinical trials.

Interested in learning more about Phase IV clinical trials? Read our full guide to Phase 4 clinical trials.

Explore the topic further

Frequently asked questions

What is the difference between PMS and PMCF?

PMS is the overarching quality and regulatory system that collects all data on a device's performance, safety and complaints. PMCF (post-market clinical follow-up) is a specific, proactive component of PMS focused exclusively on gathering and evaluating clinical data to confirm ongoing clinical safety and acceptable residual risks.

What standard governs medical device post-market surveillance?

ISO/TR 20416:2020 (Medical devices: Post-market surveillance for manufacturers) provides recognised international guidance for establishing, planning and carrying out proactive and reactive PMS systems.

Is a post-market surveillance plan mandatory for all device classes?

Yes. Under both UK MDR Part 4A and EU MDR Annex III, a documented PMS plan is mandatory for all medical device classes (Class I, IIa, IIb, III and IVDs), although the reporting documentation (PMSR or PSUR) scales with risk class.

Sources

More From Ledidi Academy